In vivo effects of pegylated recombinant human megakaryocyte growth and development factor on hematopoiesis in normal mice

Koji Kabaya, Hiromichi Akahori, Kazunori Shibuya, Yuko Nitta, Masumi Ida, Masaru Kusaka, Takashi Kato, Hiroshi Miyazaki

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

The in vivo effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF), a truncated molecule of recombinant human thrombopoietin modified with polyethylene glycol, were investigated in normal Balb/c mice. PEG-rHuMGDF was more potent in producing platelets and the dose-response curve was sleeper compared with the case of the nonpegylated form of this molecule. Five consecutive injections with PEG- rHuMGDF caused a dose-dependent increase in peripheral platelet counts with a peak on day 8. There was a dose-dependent rise in platelet counts on day 8 at daily doses from 0.333 to 30 μg/kg. Intermediate doses of PEG-rHuMGDF (1.111 to 10 μg/kg/day) caused a significant decrease in mean platelet volume, and conversely, higher doses of PEG-rHuMGDF (30 to 270 μg/kg/day) induced a dose-dependent increase in mean platelet volume. There was a dose-dependent decrease in hemoglobin concentration with a minimum on day 8 but no significant reduction in reticulocyte counts following PEG-rHuMGDF administration. White blood cell counts were unchanged by PEG-rHuMGDF treatment. Marrow megakaryocyte size enlarged in 1.5-fold and the number of marrow megakaryocytes increased to sixfold by consecutive administration of PEG-rHuMGDF at 30 μg/kg/day. A twofold increase in the number of marrow megakaryocytic progenitor cells (colony-forming units-megakaryocyte) was also observed. Marrow erythroid progenitor (colony-forming units-erythroid) counts decreased but splenic colony-forming units-erythroid, marrow and splenic erythro/myeloid progenitor cell counts, and splenic granulocyte/macrophage progenitor cell counts increased with PEG-rHuMGDF treatment. Marrow and splenic erythroid burst-forming cells were unchanged. These results indicate that PEG-rHuMGDF, a truncated molecule of thrombopoietin, is a potent stimulator for megakaryopoiesis and thrombopoiesis, and also affects the development of other hematopoietic cells in normal mice.

Original languageEnglish
Pages (from-to)651-660
Number of pages10
JournalStem Cells
Volume14
Issue number6
DOIs
Publication statusPublished - 1996 Nov

Keywords

  • Megakaryocyte
  • Megakaryocyte growth and development factor (MGDF)
  • Megakaryocytic progenitor
  • Platelet
  • Thrombopoietin (TPO)

ASJC Scopus subject areas

  • Molecular Medicine
  • Developmental Biology
  • Cell Biology

Fingerprint Dive into the research topics of 'In vivo effects of pegylated recombinant human megakaryocyte growth and development factor on hematopoiesis in normal mice'. Together they form a unique fingerprint.

  • Cite this